July 17 (Reuters) - Prima BioMed
* it will receive a second undisclosed significant clinical milestone payment from Novartis
* payment based on collaboration and licensing agreement between companies, relating to Prima's imp701 lag-3 antibody Source text for Eikon: ID:nASX21g1dG Further company coverage: NOVN.S